1	Uncovering causal gene-tissue pairs and variants: A multivariable
2	TWAS method controlling for infinitesimal effects
3	Yihe Yang ¹ , Noah Lorincz-Comi ¹ , Xiaofeng Zhu ¹
4	¹ Department of Population and Quantitative Health Sciences, School of Medicine, Case Western
5	Reserve University, Cleveland, OH, 44106, USA
6	Corresponding author: X. Zhu. xxz10@case.edu
7	Abstract
8	Transcriptome-wide association studies (TWAS) are commonly used to prioritize causal genes
9	underlying associations found in genome-wide association studies (GWAS) and have been
10	extended to identify causal genes through multivariable TWAS methods. However, recent
11	studies have shown that widespread infinitesimal effects due to polygenicity can impair the
12	performance of these methods. In this report, we introduce a multivariable TWAS method named
13	Tissue-Gene pairs, direct causal Variants, and Infinitesimal effects selector (TGVIS) to identify
14	tissue-specific causal genes and direct causal variants while accounting for infinitesimal effects.
15	In simulations, TGVIS maintains an accurate prioritization of causal gene-tissue pairs and
16	variants and demonstrates comparable or superior power to existing approaches, regardless of the
17	presence of infinitesimal effects. In the real data analysis of GWAS summary data of 45
18	cardiometabolic traits and expression/splicing quantitative trait loci (eQTL/sQTL) from 31
19	tissues, TGVIS is able to improve causal gene prioritization and identifies novel genes that were
20	missed by conventional TWAS.

It is made available under a CC-BY-ND 4.0 International license .

21 Introduction

22 Over the past two decades, genome-wide association studies (GWAS) have identified thousands 23 of genetic variants associated with complex traits^{1–3}. However, most GWAS signals are detected 24 in non-coding regions and have been shown to have complex regulatory landscapes across different tissues and cell types⁴, making it challenging to pinpoint causal variants and genes 25 26 driving these GWAS signals. Joint GWAS and expression quantitative trait loci (eQTL) data 27 analysis methods, such as colocalization⁵, transcriptome-wide association studies (TWAS)⁶, and 28 *cis*-Mendelian randomization (cis-MR)⁷, have been developed to prioritize causal genes at 29 GWAS loci⁸. Colocalization simultaneously examines the expression of a gene and a trait to 30 determine whether they share common causal genetic variants at a locus⁵. Both TWAS and *cis*-31 MR assume a causal diagram where eOTLs regulate tissue-specific gene expression that 32 subsequently affects a trait, and they identify these tissue-specific causal genes by testing the 33 significance of the causal effect estimates. Furthermore, these methods have been extended to a broader range of molecular phenotypes, such as splicing events⁹ and protein abundance¹⁰, with 34 35 regulatory QTLs being splicing QTLs (sQTLs) and protein QTLs (pQTLs), which we call 36 xQTLs in general.

Nevertheless, colocalization, TWAS, and *cis*-MR are all univariable methods that statistically measure the marginal correlations of genetic effect sizes between a trait and a tissue-specific expression of a gene. Non-causal gene-tissue pairs may be falsely detected by these univariable methods due to the *cis*-gene-tissue co-regulations with causal gene-tissue pairs^{8,11,12}. The underlying mechanism may come in the following respects: the tissue-specific eQTLs of a causal gene are in linkage disequilibrium (LD) with (1) the eQTLs of nearby non-causal genes¹³ and (2) the eQTLs of causal genes expressed in non-causal tissues¹⁴. In addition, some variants can

It is made available under a CC-BY-ND 4.0 International license .

influence a trait independently of causal gene-tissue pairs, which are frequently denoted as direct
causal variants¹³ and horizontal pleiotropy¹⁵. The non-causal gene-tissue pairs may be incorrectly
detected when their eQTLs are in LD with direct causal variants.

47 Multivariable TWAS methods, such as causal TWAS (cTWAS)¹³ and Tissue-Gene Fine-

48 Mapping (TGFM)¹⁴, have been proposed to address these issues. Specifically, cTWAS identifies 49 causal genes and direct causal variants among multiple candidates using the sum of single effects (SuSiE)^{16,14} by examining tissues separately. TGFM extends cTWAS to allow multiple tissues to 50 51 be analyzed simultaneously and can identify the trait-relevant tissues beyond the causal variants and genes. However, Cui et al.¹⁷ recently reported that current Bayesian fine-mapping methods, 52 including SuSiE^{16,18} and FINEMAP¹⁹, have a high replication failure rate (RFR) in practice. Cui 53 54 et al.¹⁷ discovered that the widespread infinitesimal effects, which may stem from the 55 polygenicity of complex traits, are the sources of the high RFR, and accounting for the 56 infinitesimal effects can reduce the RFR and improve statistical power. Similarly, the polygenicity can also lead to inflating the test statistics in standard TWAS²⁰ and traditional 57 58 linkage studies²¹. Thus, due to the lack of modeling infinitesimal effects, it is expected that 59 cTWAS and TGFM can be vulnerable to spurious prioritization and reduced statistical power.

We present the <u>T</u>issue-<u>G</u>ene pair, direct causal <u>V</u>ariants, and <u>Infinitesimal effect <u>S</u>elector
(TGVIS), a multivariable TWAS method to identify causal gene-tissue pairs and direct causal
variants while incorporating infinitesimal effects. TGVIS employs SuSiE^{16,14} for fine-mapping
causal gene-tissue pairs and direct causal variants, and uses restricted maximum likelihood
(REML)²² to estimate the infinitesimal effects. In addition, we introduce the Pratt index²³ to rank
the importance for improving the prioritization of causal genes and variants. We applied TGVIS
</u>

It is made available under a CC-BY-ND 4.0 International license .

66	to identify causal cis-gene-tissue pairs and direct causal variants for 45 cardiometabolic traits
67	using GWAS datasets with the largest sample sizes to date ^{3,24–32} , by incorporating the eQTL and
68	sQTL summary statistics from 28 tissues from genotype-tissue expression (GTEx) ¹² , and the
69	eQTL summary statistics of kidney tubulointerstitial ³³ , kidney glomerular ³³ , and pancreatic
70	islets ³⁴ tissues. We summarized the causal gene-tissue pairs and direct causal variants,
71	highlighted the pleiotropic effects at the gene-tissue level, and demonstrated the different
72	functional activity ³⁵ of eQTLs/sQTLs mediated through gene-tissues and the direct causal
73	variants. Moreover, we mapped the trait-relevant major tissues and demonstrated the
74	enrichments of genes identified by TGVIS in terms of colocalization ⁵ , on the silver standard of
75	lipid genes ¹³ , FDA-approved drug-target genes ³⁶ , and genes detected through pQTL summary
76	data ¹⁰ . Our study reveals a broader picture of gene and tissue co-regulations, which can provide
77	novel biological insights into complex traits.

78 Results

79 **Overview of method**

80 Figure 1A illustrates the causal diagram assumed in this report. Specifically, we hypothesize that 81 a set of xQTLs influence the products of genes (e.g., expressions and splicing events) at a locus. Gene co-regulation^{8,12}, i.e., the correlation of xQTL effects among multiple gene products, can 82 emerge due to shared xQTLs or being in LD among them. Meanwhile, tissue co-regulation^{11,37,38}, 83 84 defined as the correlation of gene expression across multiple tissues, can arise because of the 85 same mechanism. In the gene and tissue co-regulation network, certain gene-tissue pairs directly 86 influence a trait without mediation by other gene-tissue pairs, which are referred to as causal 87 gene-tissue pairs. In addition, some genetic variants may directly influence the trait, which we 88 consider as direct causal variants. Besides these direct causal variants which have relatively large

It is made available under a CC-BY-ND 4.0 International license .

effects, we assume there are polygenic or infinitesimal effects that can be modeled through a
normal distribution with mean zero and small variance¹⁷ (Method).

91 The curse of dimensionality poses a substantial challenge in the multivariable TWAS model. 92 **Figure 1B** illustrates this challenge by an example of the association evidence with low-density lipoprotein cholesterol $(LDL-C)^1$ at the *PCSK9* locus, where dozens of coding genes and long 93 94 non-coding ribonucleic acids (RNAs) are located, along with multiple potential direct causal 95 variants. Conventional statistical methods cannot precisely identify causal gene-tissue pairs and 96 variants because there are many correlated candidates which frequently range from hundreds to 97 thousands¹⁶. The proposed TGVIS enables to overcome the curse of dimensionality. Figure 1C 98 describes the workflow of TGVIS, where the inputs are the GWAS summary statistics of a 99 trait, xOTL summary statistics of gene-tissue pairs, and a reference LD matrix of the 100 variants at the locus. TGVIS utilizes a profile-likelihood approach to estimate the causal effects of gene-tissue pairs and directly causal variant effects with SuSiE^{16,18} and model the 101 102 infinitesimal effects via REML²². This profile-likelihood iterates until all estimates are 103 converge. The details are described in the **Methods** and the **Supplementary Materials**. 104 In practice, another challenge arises when selecting a causal gene-tissue pair based solely on its 105 posterior inclusion probability (PIP) because many gene-tissue pairs share the same sets of 106 xOTLs at a locus, making them statistically indistinguishable. SuSiE groups these pairs into a 107 credible set during fine-mapping and introduces a single effect to describe the contributions of 108 the variables in the same credible set. Therefore, all inferences should be made based on the 109 single effects defined by SuSiE's credible sets. To quantify the contribution of each gene-tissue pair and direct causal variant, we introduce the Pratt index²³ as a metric parallel to PIP. While 110 111 PIP measures the significance of variables from a Bayesian viewpoint, the Pratt index quantifies

It is made available under a CC-BY-ND 4.0 International license .

their predictive importance. In the application, we calculated the cumulative Pratt index of

113 variables in a 95% credible set (CS-Pratt) and filtered out the credible sets with low CS-Pratt

114 values (Methods and Supplementary Materials). We observed that this procedure improved

the precision of causal gene and variant identification.

116 Simulation

117 We compared the TGVIS with 4 multivariable MR and TWAS methods: *cis*IVW³⁹, Grant2022⁴⁰,

118 cTWAS¹³, and TGFM¹⁴. We applied the following criteria for determining the causality: the

119 95% credible set for TGVIS, TGFM, and cTWAS; P < 0.05 for *cis*IVW; and selection by lasso

120 in the Grant2022. We did not consider univariable methods because of their high type-I error

121 rates when the goal is to identify causal genes, given that xQTL effect sizes for multiple genes

are often correlated¹³. Detailed information on the settings and results can be found in the

123 Methods and Supplementary Materials.

124 We first assessed the accuracy of causal effect estimation for gene-tissue pairs. When 125 infinitesimal effects were absent, TGVIS showed a mean square error (MSE) for causal effect 126 estimates similar to that of cTWAS, and TGFM, while both *cis*IVW and Grant2022 exhibited 127 substantially larger MSE (as shown in the left two panels in Figure 2A). However, when 128 infinitesimal effects were present, TGVIS demonstrated a visibly lower MSE compared to the 129 other methods, with cTWAS and TGFM showing approximately 32% higher MSE than TGVIS 130 (as shown in the right two panels in **Figure 2A**). These results indicate that TGVIS generally 131 outperforms its competitors by accounting for infinitesimal effects.

132 We then compared the true negative rate (TNR) and true positive rate (TPR) of these five

133 methods. A true negative is defined as a method that correctly identifies all 98 non-causal gene-

134	tissue pairs. Similarly, a true positive is defined as a method that correctly identifies the 2 causal
135	gene-tissue pairs. Across all the scenarios (Figure 2B), TGVIS achieved the highest TNR, with
136	an average of 0.614, followed by TGFM and cTWAS, with average TNRs of 0.513 and 0.499,
137	respectively. CisIVW and Grant2022 performed worst, with averages TNR of 0.064 and 0.013,
138	respectively, indicating that these two methods are prone to identifying a substantial number of
139	false positive gene-tissue pairs. On the other hand, TGVIS exhibited a similar TPR (average
140	TPR = 0.667) as TGFM, cTWAS, and <i>cis</i> IVW (average TPRs of 0.649, 0.667, and 0.661,
141	respectively), while Grant2022 had the highest TPR (averages TPR= 0.831) (Figure 2C), which
142	is not surprising given that Grant2022 also has lowest TNR.
143	We further assessed the performance in detecting direct causal variants. In scenarios where no
144	direct causal variants were present, the TGVIS identified fewer direct causal variants, with an
145	average number of 0.92, compared to 2.39 for TGFM and 2.38 for cTWAS (Figure 2D). When
146	there were two direct causal variants present, TGVIS identified an average of 2.86 direct causal
147	variants, compared to 3.58 for both cTWAS and TGFM. The averaged correlations between the
148	estimated and true direct causal effects across simulations were high for all three methods
149	(Figure 2E). However, predicting infinitesimal effects remains challenging, as evidenced by an
150	average correlation of 0.663 between the predicted and true infinitesimal effects in TGVIS
151	(Figure 2F).
152	Searching potentially causal gene-tissue pairs and variants for 45 cardiometabolic traits
153	We systematically analyzed 45 cardiometabolic traits and eQTL/sQTL summary statistics (Table
154	S1-S2) to identify potential causal gene-tissue pairs and direct causal variants. For the TVGIS,
155	we considered whether a gene-tissue pair or direct causal variant was causal if (1) it was within a

156 95% credible set and (2) had a CS-Pratt > 0.15. The criteria of CS-Pratt > 0.15 was established

- 157 based on the empirical evidence (**Methods**). For TGFM, we followed the authors'
- 158 recommendation of considering individual PIP > 0.5 as indicative of causality. Additionally, we
- did not compare with cTWAS because it analyzes tissues separately¹³.
- 160 TGVIS and TGFM identified a median of 119.5 and 227.5 causal gene-tissue pairs, and 42 and
- 161 183 causal variants per trait (**Figure 3A, Table S3-S6**), respectively. Additionally, TGVIS
- detected a median of 0.313 causal gene-tissue pairs and 0.115 direct causal variants per locus,
- 163 while TGFM identified a median of 0.469 causal gene-tissue pairs and 0.466 direct causal
- 164 variants per locus (Figure 3C). Overall, TGVIS reduced the number of causal gene-tissue pairs
- by a median of 55.7% and the number of direct causal variants by 24.5% per trait compared to
- 166 TGFM, representing the improved resolution of TGVIS over TGFM.
- 167 We expected that general causal gene-tissue pairs detected by TGVIS and TGFM would likely
- 168 be included among those identified by univariable TWAS methods such as S-PrediXcan⁴¹.
- 169 Surprisingly, among the causal pairs identified by TGVIS, a median of 34.3% were undetected
- 170 by S-PrediXcan, and this proportion was 60.1% for TGFM (Figure 3A, Table S22). For
- 171 example, TGVIS identified *SCN2A*-Nerve_Tibial as a novel causal gene-tissue pair for 17 traits
- 172 (Figure S37) but missed by TWAS. Both TGVIS and TWAS identified *SCN2A*-Nerve_Tibial for
- type 2 diabetes. Our findings suggest *SCN2A* may regulate a wide range of metabolic traits.
- 174 These results indicate that TGVIS not only fine-maps causal genes detected but also uncovers
- 175 novel genes by modeling multiple tissue-gene pairs simultaneously.
- 176 We investigated how many traits can be influenced by a causal gene-tissue pair, reflecting the
- 177 pleiotropic effect at the gene-tissue level. Among the causal gene-tissue pairs falling in credible
- sets of size less than 2, 22.4% identified by TGVIS and 16.7% by TGFM exhibit pleiotropic

It is made available under a CC-BY-ND 4.0 International license .

effect (Figure 3D, Table S7-S8), indicating that many of these causal genes contribute to shared
biological mechanisms across multiple traits.

181 We further examined whether the direct causal variants and xQTLs mediated by causal gene-182 tissue pairs differ in functionality using functional annotations³⁵ (Methods). Significant 183 differences were observed between these two types of variants identified by either TGVIS or 184 TGFM across multiple annotations (**Table S11**). As shown in **Figure 3E** and **3F**, the direct 185 causal variants generally have higher FathmmXF and h3k9me3 scores than the xQTLs mediated 186 by causal gene-tissue pairs (Wilcoxon signed-rank test, P<2.2E-16), suggesting distinct 187 biological mechanisms for many of these variants. 188 We observed that multiple eGenes and sGenes often shared the same set of variants as their 189 xQTL, highlighting the importance of making inferences based on credible sets rather than 190 individual variables. Most credible sets consisted of 2 to 4 gene-tissue pairs (60.5%), although 191 some credible sets included more than 10 (11.5%) for TGVIS (Figure 4A, Table S12). In 192 comparison, TGFM resulted predominantly featured single gene-tissue pairs (56.0%) and 2 to 4 193 pairs (41.7%) per credible set (Figure S18, Table S12). On the other hand, most of the credible 194 sets only had one xQTL (66.6%), followed by two xQTLs (12.6%) for TGVIS (Figure 4B. 195 Table S13). As for TGFM, these percentages were 26.9% for one xQTL and 24.4% for two xQTLs (Figure S20, Table S13). These differences arise because TGFM resampled all xQTLs 196 197 in the 95% credible sets, typically incorporating more variants, whereas TGVIS applied a stricter 198 criterion for selecting xQTLs (Methods, Figure S18-S19).

199 We investigated the proportions of identified causal eGenes and sGenes for the 45

200 cardiometabolic traits (Methods). TGVIS showed eGenes and sGenes proportions of 58.1% and

41.9%, respectively, while TGFM resulted in 63.5% for eGenes and 36.5% for sGenes (Figure

It is made available under a CC-BY-ND 4.0 International license .

4C, Figure S21). These results align with the proportions observed in the GTEx Consortium
(63% *cis*-eQTL vs. 37% *cis*-sQTL)¹², with TGFM's proportions being slightly closer. A potential
explanation is that TGVIS' eGenes and sGenes were more likely enriched for causal genes
specific to cardiometabolic traits, leading to a slight difference, though this difference is not
substantial.

207 We calculated the Pratt index of gene-tissue pairs, direct causal variants, and infinitesimal effects 208 based on its additive property (Figure 4D, Table S15), which helps measure the contributions of 209 these three potentially correlated components (Methods). For TGVIS, the median of the Pratt 210 index was 0.161, 0.059, and 0.182 for gene-tissue pairs, direct causal variants, and infinitesimal 211 effects, respectively, with a median sum of the Pratt index of 0.403. In comparison, for TGFM, 212 the median of the Pratt index was 0.145 for gene-tissue pairs and 0.114 for direct causal variants, 213 with a median sum of the Pratt index of 0.262. These results support the existence of widespread 214 infinitesimal effects.

215 Major relevant tissue map of cardiometabolic traits

216 We searched the major relevant tissues by counting their numbers to the causal gene-tissue pairs 217 in credible sets identified by TGVIS and TGFM (Methods). We ranked the top relevant tissues 218 according to their contributions and clustered similar traits and tissues based on the similarity of 219 the identified causal gene-tissue pairs (Figure 5A-5B, Figure S22-S23). Overall, we observed 220 similar major relevant tissues and clustering patterns using both methods, although there were 221 some notable differences. TGVIS tended to cluster similar traits more closely together than 222 TGFM. For instance, TGVIS grouped all blood pressure traits into close clusters, placing them 223 near coronary artery disease (CAD), whereas TGFM positioned systolic and diastolic blood 224 pressures (SBP and DBP) farther from pulse pressure (PP) and CAD. Similarly, serum lipid traits

It is made available under a CC-BY-ND 4.0 International license .

were clustered together by TGVIS, but not by TGFM. On the other hand, arterial tissues
consistently emerged as the major tissue for blood pressure traits and CAD, while heart tissues
were the major tissue for the QRS complex, atrial fibrillation, QT interval, and JT interval.
Fibroblasts were highlighted as an important tissue for many traits, aligning with recent findings
about their role in tissue integrity and chronic inflammation, alongside other tissues such as
adipose tissue and liver⁴².

231 We considered several lipids traits, including LDL-C, HDL-C, TC, triglyceride,

apolipoprotein A1 (APOA1), and apolipoprotein B (APOB), as examples to illustrate the

233 proportional counts of each tissue identified in the credible sets. For HDL-C and triglycerides,

the most relevant tissue was subcutaneous adipose (Figure 5C). In contrast, liver tissue was

235 consistently the most relevant tissue for LDL-C, APOB, and TC, despite the small sample size

for the liver tissue gene expression data¹². For APOA1, the two most relevant tissues were the

237 liver and subcutaneous adipose tissue. Figures S24-S32 display the plots of major tissues for the

rest of the traits. Overall, the TGVIS and TGFM produced in general consistent results.

239 Evaluation of the identified gene-tissue pairs

240 To evaluate the accuracy of the prioritization of causal gene-tissue pairs, we first compared the 241 colocalization evidence of the causal credible sets identified by TGVIS and TGFM through Coloc-SuSiE⁵. Since a credible set could include multiple tissue-gene pairs, we defined a 242 243 colocalization of a credible set in two criteria: (1) the credible set contained at least one gene-244 tissue pair that is colocalized with the trait; (2) more than 50% of the gene-tissue pairs in the 245 credible set were colocalized with the trait (Method). TGVIS had much higher proportions of 246 colocalized credible sets (the median proportions across traits were 93.1% and 77.8% for the two 247 criteria, respectively) than TGFM (the median proportions across traits were both 40.9% for two

It is made available under a CC-BY-ND 4.0 International license .

- 248 criteria) (Figure 6A and Table S16-S17), suggesting a substantial number of causal tissue-gene
- 249 pairs identified by TGFM do not have colocalization evidence.
- 250 We next followed the previous analysis strategy¹³ to assess the causal genes for LDL-C
- 251 identified by TGVIS and TGFM. Precision was evaluated using the 69 known lipid-related genes
- as the silver standard positive gene set, and nearby genes within a 1MB-radius region as the
- 253 negative set, as studied by Zhao et al.¹³. We disregarded the tissue part of the identified causal
- 254 gene-tissue pairs and then calculated how many causal genes were within the lists of sliver and
- 255 nearby genes. TGVIS demonstrated a precision of 60.0% (9 out of 15), outperforming TGFM,
- which had a precision of 37.5% (10 out of 28) (**Table S18** and **Figure S33**).
- 257 It is reasonable to assume that causal genes are more likely to be druggable targets. We utilized
- the published list of 6,690 FDA/EMA-approved non-cancer drugs (**Table S1** provided by
- 259 Trajanoska et al.³⁶) to calculate the enrichment of the identified causal genes in the drug list
- 260 (Figure 6B and Table S19-S20). Although the number of causal genes identified by TGVIS in
- the drug-targeted gene list was only 74.3% of that identified by TGFM, the enrichment identified
- 262 by TGVIS was 1.43 times more than that by TGFM (P = 1.56E-3).

We hypothesized that causal genes detected through eQTLs/sQTLs may be more likely to
demonstrate association evidence in protein data. To test this, we conducted univariable MR
analysis of protein abundances (pGenes) in blood tissue for genes identified by TGVIS and

- TGFM, using both *trans* and *cis*-pQTLs as instrument variables (Figure 6C and Table S21). On
- average, 18.1% of pGenes identified by TGVIS showed significant causal evidence, compared to
- 268 13.7% of pGenes for TGFM (P = 3.1E-3). However, this proportion is lower than the estimated
- true positive association rate of 27.8% between predicted *cis*-regulated gene expression and
- 270 plasma protein abundances⁴³. The discrepancy may arise from the fact that pGenes are

It is made available under a CC-BY-ND 4.0 International license .

influenced by widespread *trans*-pQTLs¹⁰, whereas predicted gene expression is predominantly 271 272 contributed by cis-eQTLs, and its trans-regulated effects are much more difficult to detect. This 273 result suggests that eGenes/sGenes and pGenes may represent distinct biological processes 274 related to complex traits⁴³. 275 Fine-mapping of causal gene-tissue pairs and variants in GWAS loci 276 We exemplified four loci associated with LDL-C, CAD, and BMI. The first locus contains the 277 *PCSK9* gene for LDL-C (Figure 7A). TGVIS identified three 95% credible sets, including 278 *PCSK9*-Whole_Blood and two direct causal variants *rs11591147* and *rs11206517* (Figure 7B). 279 After applying the threshold of CS-Pratt > 0.15, *PCSK9*-Whole_Blood (CS-Pratt = 0.17) and 280 rs11591147 (CS-Pratt = 0.492) remained. In contrast, TGFM identified nine gene-tissue pairs and direct causal variants with PIPs > 0.5 (Figure 7C), including the *MROH7*-281 282 Esophageal_Mucosa which has no clear connection to the biology of LDL-C. Applying the CS-283 Pratt threshold, *PCSK9*-Whole_Blood (CS-Pratt = 0.204) and *rs11591147* (CS-Pratt = 0.524) 284 remained, consistent with the results yielded by TGVIS. This example demonstrates how TGVIS 285 reduces false positives by modeling infinitesimal effects and applies the Pratt Index as an 286 additional criterion. The second locus contains the *HMGCR* gene causal⁴⁴ to LDL-C (Figure 7D). TGVIS identified 287

five 95% credible sets (Figure 7E). The first credible set (the darkest green) includes 9 gene-

tissue pairs, such as *HMGCR*-Muscle_Skeletal and five of its sGenes in esophagus mucosa,

290 nerve tibial, fibroblasts, and adipose visceral, all sharing the same xQTL *rs2112653*. When we

applied the threshold of individual PIP > 0.5, none of the pairs in this credible set were selected

although they were all in a 95% credible set. However, this set had the highest CS-Pratt of 0.322

among the five 95% credible sets. Conversely, TGFM identified *POLK*-Lung (CS-Pratt = 0.684)

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24317250; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

but missed the crucial *HMGCR* gene (Figure 7F). This is likely a false discovery, as *HMGCR*inhibitor is a key component of statins, which works by inhibiting HMG-CoA reductase and thus
reduces LDL-C in the blood⁴⁴.

- In the third example, we focused on the *PHACTR1* locus related to CAD (Figure 7G). Both
- 298 TGVIS and TGFM identified a major credible set at this locus, including PHACTR1-
- Artery_Coronary and *PHACTR1*-Artery_Aorta, with CS-Pratt values of 0.632 and 0.612,
- 300 respectively (Figure 7H-7I). In TGVIS, the individual PIPs of them were both 0.5 and the
- 301 cumulative PIP for this credible set was 1. In contrast, TGFM resampled both the eQTL effect
- 302 estimates and the PIPs (Methods), resulting in a higher individual PIP and Pratt index for
- 303 *PHACTR1*-Artery_Aorta (PIP = 0.597, Pratt = 0.472) than *PHACTR1*-Artery_Coronary (PIP =
- 0.222, Pratt = 0.053). However, as noted by Strober et al.¹⁴, this resampling process tends to
- 305 favor gene-tissue pairs with larger sample sizes, which may explain the exclusion of PHACTR1-
- 306 Artery_Coronary. TGVIS adheres to the original interpretation of SuSiE that the variables within
- 307 a credible set cannot be distinguished from the available data.
- 308 The final exemplary locus is the *FTO* locus associated with BMI (Figure 7J). TGVIS identified
- 309 only two direct causal variants rs7206790 and rs3751813 and did not find any gene-tissue pairs
- 310 at this locus (**Figure 6K**). In contrast, TGFM identified four gene-tissue pairs:
- 311 FTO_Kidney_Glomerulus, FTO_Thyroid, FTO_Artery Tibial, and IRX3-
- 312 Adipose_Subcutaneous, and five direct causal variants (Figure 7L). However, the associations
- 313 between obesity and the expression of the *FTO* gene in the kidney glomerulus, thyroid, and tibial
- artery are not well-established in the literature. After applying the Pratt index threshold, only two
- direct causal variants *rs7206790* and *rs3751813*, remained, consistent with the result from the
- TGVIS. When we reduced the locus radius from 1MB to 500KB and re-ran the analysis, both

It is made available under a CC-BY-ND 4.0 International license .

317 TGVIS and TGFM identified the sGene of *FTO*-Pancreas as causal, with CS-Pratt values of

318 0.345 and 0.407, respectively (Figure S35). The sQTLs of this FTO sGene are rs7206790 and

rs11642841, which have been reported by Xu et al.⁴⁵. This example suggests that when applying

320 multivariable TWAS methods, the size of a *cis*-region can be sensitive and need to be calibrated.

321 Discussion

322 In this report, we developed TGVIS to identify causal gene-tissue pairs and direct causal variants

323 in loci identified through GWAS by integrating xQTL summary statistics. Compared to

324 cTWAS¹³ and TGFM¹⁴, TGVIS not only analyzes multiple tissue-specific xQTL summary data

325 simultaneously to pinpoint causal gene-tissue pairs and direct causal variants, but also models the

326 widespread presence of infinitesimal effects underlying polygenic traits to reduce false discovery

rates in detecting causal molecular phenotypes¹⁷. In addition, TGVIS quantifies the importance

328 of a causal variable by the Pratt index, which has been well established in statistics and has

recently been applied to estimate the gene-by-environment contribution²³. Through simulations,

330 we demonstrated that under the presence of infinitesimal effects, TGVIS has lower MSE and

higher TPR and TNR compared to both cTWAS and TGFM (Figure 2). In real data analysis,

332 TGVIS outperformed TGFM in the following four aspects: (1) identifying more interpretable

333 major trait-relevant tissues (Figure 5); (2) resulting in a higher proportion of colocalized causal

334 credible sets (93.1% vs 40.9%, **Figure 6A**); (3) achieving notably higher precision in the 'silver

standard' sets of lipids (60.0% vs 37.5%, **Table S15**); and (4) demonstrating significantly greater

enrichment evidence based on druggable genes (1.43 times, Figure 6B) and causal proteins (1.31
times, Figure 6C).

338 Our analysis of 45 cardiometabolic traits provides several key insights. First, we identified a

339 median of 34.3% causal gene-tissue pairs that were missed in univariable TWAS analysis,

340 suggesting that TGVIS is able to identify novel genes besides fine-mapping the genes detected 341 by conventional TWAS (Figure 3A), representing a significant advance in TWAS. Second, we 342 observed that infinitesimal effects can make a substantial contribution to local genetic variation 343 of traits besides the gene-tissue pairs and direct variant (Figure 4D), which is consistent with 344 recent studies^{17,21,46}. Beyond underlying biological mechanisms such as the polygenicity of 345 human complex traits, the emergence of infinitesimal effects may also be attributed to non-346 biological factors, particularly estimation errors in the LD matrix, xQTL effect sizes, and trait 347 GWAS imputation (Method). Both empirical observations and theoretical investigation 348 underscore the importance of including infinitesimal effects in future genetic researches and 349 methodological developments. Third, our study indicates that a significant proportion of causal 350 gene-tissue pairs (22.4%) exhibit pleiotropic effects at the gene-tissue level, suggesting shared 351 biological mechanisms across multiple traits (Figure 3D, Table S7-S8). Fourth, our findings 352 suggest that for most traits, only a limited number of relevant major tissues are involved (Figure 353 **4A**), implying that concentrating multi-omics data analyses on these relevant major tissues can 354 be more powerful and efficient, as well as it can make the findings more biologically 355 interpretable. For example, when the analysis is focused on the four major blood-pressure-356 relevant tissues, i.e., adrenal gland, artery, heart, and kidney, it leads to the identifications of 357 more causal gene-tissue pairs, with an increased Pratt index for blood pressure traits⁴⁷. Fifth, our 358 results indicate that only 18.1% of causal genes from eQTL/sQTL analyses also show causal 359 evidence in univariable MR using pQTL summary data (Figure 6C), suggesting that gene 360 expressions and protein abundance represent distinct biological processes in complex traits⁴³. 361 Finally, we identified an average of 0.304 causal gene-tissue pairs per locus and failed to identify 362 any causal gene-tissue pairs in many GWAS loci (Figure 3A), which is consistent with the

It is made available under a CC-BY-ND 4.0 International license .

363 recent study showing that the GWAS and eQTL studies are systematically biased toward 364 different types of variants⁴. Interestingly, the eQTLs/sQTLs of causal gene-tissue pairs and direct 365 causal variants have substantially different functional annotations (Figure 3E-3F, Table S11), 366 warranting further investigation. 367 Our study has some limitations. Due to the data and computational constraints, we only analyzed 368 genes using *cis*-eQTL/sQTL summary statistics, limiting our ability to distinguish between genes 369 that share *cis*-eQTLs/sQTLs, which may lead to false discoveries. This issue could potentially be 370 addressed by incorporating *trans*-eOTLs/sOTLs, although this would require much larger sample 371 sizes. In addition, we observed that a credible set often contains 2-4 gene-tissue pairs (Figure 372 **3C**), likely due to the small sample size in the GTEx data, which results in only 1 or 2 373 eQTL/sQTL for most gene-tissue pairs (Figure 4B). In other words, while TGVIS was able to 374 narrow down to a range of causal gene-tissue pairs, it could not always pinpoint the exact causal 375 pair(s) in some loci. Incorporating external information, such as colocalization evidence with 376 TGVIS, may aid in distinguishing these pairs⁴⁸. Furthermore, our eOTL/sOTL analysis relies on 377 bulk tissue expression data, which may limit our ability to identify cell-type-specific causal 378 genes⁴⁹. For example, recent studies increasingly suggest that *FTO* may not be the causal gene 379 for BMI; instead, experimental evidence indicates that *IRX3* and *IRX5* are the causal genes⁵⁰. 380 However, the causality of *IRX3* and *IRX5* was observed in experiments using preadipocytes, 381 rather than bulk subcutaneous adipose tissue, which may explain why TGVIS failed to identify these genes (Figure S36). Moreover, we used the Pratt index²³ to rank the importance of 382 variables, but it has inherent statistical limitations²³. In simulations, the Pratt index slightly 383 384 underestimates the true contribution, although this underestimation becomes negligible as the 385 sample size increases (Figure S1-S8). In real data analysis, we used an empirical cutoff learned

- by K-means (CS-Pratt = 0.15) to extract important causal variables, which gives us higher
- 387 precision but may have potentially hindered the discovery of causal gene-tissue pairs with small
- to moderate causal effects. Last, as suggested in previous studies¹⁴, the inference of causality
- based on statistical methods comes with a caveat, assuming no model misspecification and no
- 390 potential causal elements are missing from the model.
- 391 In summary, our developed TGVIS and accompany software pipeline provide a valuable tool in
- 392 fine-mapping and interpreting GWAS findings.

It is made available under a CC-BY-ND 4.0 International license .

393 Methods

394 Multivariable TWAS model

The causal diagram shown in Figure 1A can be described by the following multivariable TWASmodel:

397
$$\mathbf{y} = \sum_{j=1}^{J} \sum_{t=1}^{T} X_{jt} \,\theta_{jt} + \mathbf{G}^{\mathsf{T}}(\mathbf{\gamma} + \mathbf{\upsilon}) + \varepsilon, \quad (1)$$

398 where y is a trait, X_{jt} is the jt^{th} gene-tissue pair, $\mathbf{G} = (G_1, \dots, G_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector of

399 genetic variants in the *cis*-region, $\boldsymbol{\theta} = (\theta_{11}, ..., \theta_{JT})^{\mathsf{T}}$ is an $(JT \times 1)$ vector of causal effects with 400 θ_{jt} being the causal effect of the (j, t)th tissue-gene pair, $\boldsymbol{\gamma} = (\gamma_1, ..., \gamma_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector 401 of direct causal effects, $\boldsymbol{\upsilon} = (\upsilon_1, ..., \upsilon_M)^{\mathsf{T}}$ is an $(M \times 1)$ vector of infinitesimal effects, and ϵ is 402 the random error. Let $\boldsymbol{\beta}_{jt} = (\beta_{jt1}, ..., \beta_{jtM})^{\mathsf{T}}$ is an $(M \times 1)$ vector of the *cis*-eQTL effects of *JT* 403 tissue-gene pairs. Then we have

404
$$X_{jt} = \mathbf{\beta}_{jt}^{\mathsf{T}} \mathbf{G} + \epsilon_{jt}, \quad (2)$$

405 where ϵ_{jt} is the noise of the jt^{th} gene-tissue pair. The reduced form of (1) is then given by:

406
$$y = \mathbf{G}^{\mathsf{T}} \left(\sum_{j=1}^{J} \sum_{t=1}^{T} \boldsymbol{\beta}_{jt} \, \theta_{jt} + \boldsymbol{\gamma} + \boldsymbol{\upsilon} \right) + \epsilon, \quad (3)$$

407 where mathematically $\epsilon = \varepsilon + \sum_{j=1}^{J} \sum_{t=1}^{T} \epsilon_{jt} \theta_{jt}$.

408 An alternative version of (1) based on summarized statistics⁵¹ is:

It is made available under a CC-BY-ND 4.0 International license .

409
$$\hat{\mathbf{a}} \sim \mathcal{N}\left(\mathbf{R}\left(\sum_{j=1}^{J}\sum_{i=1}^{T}\boldsymbol{\beta}_{jt}\,\theta_{jt}+\boldsymbol{\gamma}+\boldsymbol{\upsilon}\right),\sigma_{\alpha}^{2}\mathbf{R}\right),\quad(3)$$

410 where $\hat{\mathbf{a}} = (\hat{a}_1, ..., \hat{a}_M)^{\mathsf{T}}$ represents the GWAS effects of the outcome, **R** is an $(M \times M)$ LD 411 matrix of the *M* variants, and σ_{α}^2 is the variance of this model. The eQTL effect vector $\boldsymbol{\beta}_{jt}$ 412 follows the model based on summarized statistics below:

413
$$\hat{\mathbf{b}}_{jt} \sim \mathcal{N}\left(\mathbf{R}\boldsymbol{\beta}_{jt}, \sigma_{\boldsymbol{\beta}_{jt}}^{2}\mathbf{R}\right), \quad (5)$$

414 where $\hat{\mathbf{b}}_{jt} = (\hat{b}_{jt1}, ..., \hat{b}_{jtM})^{\mathsf{T}}$ represents the marginal *cis*-eQTL effect estimates for the *jt*th 415 tissue-gene pair, and $\sigma_{\beta_{jt}}^2$ denotes the variance of this model.

416 To resolve this curse of dimensionality, we utilized the three sparsity conditions that are commonly assumed in current fine-mapping methods^{16,19}: (SP1) one or small number of variants 417 causally contribute to tissue or cell-type specific gene expression¹²; (SP2) one or small number 418 of gene-tissue pairs causally contribute to the trait^{13,14}; (SP3) one or small number of direct 419 causal variants exist with relatively large effect sizes^{13,14}. In terms of statistical model: SP1 420 421 corresponds to β_{it} being sparse for all j and t; SP2 corresponds to θ being sparse; SP3 422 corresponds to \mathbf{v} being sparse. In addition, we incorporated that variants can have infinitesimal effects: \mathbf{v} is normally distributed with a mean 0 and a small, unknown variance ¹⁷. To our best 423 424 knowledge, infinitesimal effects have not been modeled in current multivariable TWAS 425 methods.

426 Estimation of *cis*-regulatory effect

It is made available under a CC-BY-ND 4.0 International license .

TGVIS first applies SuSiE¹⁸ to estimate the non-zero eQTL effect for each gene-tissue pair, 427 428 based on the fine-mapping model (Equation 5). Specifically, we set L = 3 for each pair and 429 determined the non-zero *cis*-regulatory effects based on two criteria: (1) if they are within any 430 95% credible set and their PIPs exceeds 0.25, and (2) if their individual PIPs are greater than 0.5. 431 The rationale behind this approach is that SuSiE's 95% credible set can sometimes include too 432 many weakly correlated variants (even after removing highly correlated ones using LD 433 clumping), leading to low PIPs for each variant. Therefore, we used a moderate threshold to filter 434 out credible sets with too many variants. Additionally, due to the low power of detection, the 435 maximum PIP of credible sets might fall below 0.95, so we retained variants with individual 436 PIPs greater than 0.5. Since a locus often contains over 10,000 gene-tissue pairs (mostly sGenes), 437 dynamically selecting using BIC would be computationally burdensome. Additionally, with 438 GTEx sample sizes under 200, only 1-2 gene-tissue pairs can be identified for most gene-tissue 439 pairs. Therefore, we choose to fix L = 3.

Joint modelling of causal tissue-gene pairs, direct causal variants, and infinitesimal effects using profile likelihood

442 TGVIS estimates θ , γ , and υ using a profile likelihood approach. Given the estimate $\upsilon^{(s)}$ from 443 the sth iteration, we considered the following fine-mapping model:

444
$$\hat{\mathbf{a}} - \mathbf{R}\mathbf{v}^{(s)} \sim \mathcal{N}(\mathbf{R}\mathbf{\gamma} + \mathbf{R}\hat{\mathbf{B}}\mathbf{\theta}, \sigma_{\alpha}^{2}\mathbf{R}),$$
 (6)

445 where $\widehat{\mathbf{B}} = (\widehat{\boldsymbol{\beta}}_{11}, ..., \widehat{\boldsymbol{\beta}}_{jt}, ..., \widehat{\boldsymbol{\beta}}_{JT})$ is an $M \times JT$ matrix consisting of estimated *cis*-regulatory 446 effects. To update $\boldsymbol{\gamma}$ and $\boldsymbol{\theta}$ simultaneously, we applied the same scheme as cTWAS and TGFM, 447 using the function susie_rss(·). The input z-score vector is computed as:

It is made available under a CC-BY-ND 4.0 International license .

448
$$z = \left(\frac{\widehat{\boldsymbol{\beta}}_{11}^{\mathsf{T}}\widehat{\boldsymbol{a}}}{\sqrt{\widehat{\boldsymbol{\beta}}_{11}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{11}}}, \cdots, \frac{\widehat{\boldsymbol{\beta}}_{JT}^{\mathsf{T}}\widehat{\boldsymbol{a}}}{\sqrt{\widehat{\boldsymbol{\beta}}_{JT}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{JT}}}, \widehat{a}_{1}, \cdots, \widehat{a}_{M}\right)^{\mathsf{T}}, \quad (7)$$

and the other elements of input correlation matrix are computed as:

450
$$\operatorname{cor}(\mathbf{G}_{i}\widehat{\boldsymbol{\beta}}_{jt},\mathbf{G}_{i}\widehat{\boldsymbol{\beta}}_{j't'}) = \frac{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{j't'}}{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{jt}}\sqrt{\widehat{\boldsymbol{\beta}}_{j't'}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{j't'}}},$$

451
$$\operatorname{cor}(\mathbf{G}_{\mathbf{i}}\widehat{\boldsymbol{\beta}}_{jt},\mathbf{G}_{\mathbf{i}}) = \frac{\mathbf{R}\widehat{\boldsymbol{\beta}}_{jt}}{\sqrt{\widehat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}}\mathbf{R}\widehat{\boldsymbol{\beta}}_{jt}}}, \quad \operatorname{cor}(\mathbf{G}_{\mathbf{i}}) = \mathbf{R}, \quad (8)$$

452 The outputs are denoted as $\gamma^{(s+1)}$ and $\theta^{(s+1)}$.

453 Next, we consider the following model:

454
$$\hat{\mathbf{a}} - \mathbf{\eta}^{(s+1)} | \mathbf{v} \sim \mathcal{N}(\mathbf{R}\mathbf{v}, \sigma_{\alpha}^2 \mathbf{R}), \quad \mathbf{v} \sim \mathcal{N}(\mathbf{0}, \sigma_{v}^2 \mathbf{I}), \quad (9)$$

455 where $\mathbf{\eta}^{(s+1)} = \mathbf{R}(\mathbf{\hat{B}}\mathbf{\theta}^{(s+1)} + \mathbf{\gamma}^{(s+1)})$. The penalized quasi-likelihood (PQL) of \mathbf{v} is

456
$$\mathbf{v}^{(s+1)} = \arg\min_{\mathbf{v}} \left\{ \left(\hat{\mathbf{a}} - \mathbf{\eta}^{(s+1)} - \mathbf{R}\mathbf{v} \right)^{\mathsf{T}} \mathbf{R}^{-1} \left(\hat{\mathbf{a}} - \mathbf{\eta}^{(s+1)} - \mathbf{R}\mathbf{v} \right) + \frac{\sigma_{\alpha}^{(s)2}}{\sigma_{v}^{(s)2}} \| \mathbf{v} \|_{2}^{2} \right\}, \quad (10)$$

457 which results in

458
$$\mathbf{v}^{(s+1)} = \left(\mathbf{R} + \frac{\sigma_{\alpha}^{(s)2}}{\sigma_{v}^{(s)2}}\mathbf{I}\right)^{-1} \left(\hat{\mathbf{a}} - \mathbf{\eta}^{(s+1)}\right), \quad (11)$$

459 where $\sigma_{\alpha}^{(s)2}$ is the current variance estimate. The variance $\sigma_{v}^{(s)2}$ is updated by REML:

It is made available under a CC-BY-ND 4.0 International license .

460
$$\sigma_{v}^{(s+1)2} = \arg\min_{\sigma_{v}^{2}} \left\{ \frac{\| \mathbf{v}^{(s+1)} \|_{2}^{2}}{\sigma_{v}^{2}} + M \log(\sigma_{v}^{2}) + \log \det \left(\frac{1}{\sigma_{\alpha}^{(s)2}} \mathbf{R} + \frac{1}{\sigma_{v}^{(s)2}} \mathbf{I} \right) \right\}, \quad (12)$$

461 which simplifies to

462
$$\sigma_{v}^{(s+1)2} = \frac{1}{M} \| \mathbf{v}^{(s+1)} \|_{2}^{2} + \frac{1}{M} \operatorname{tr}\left(\left(\mathbf{R} + \frac{\sigma_{\alpha}^{(s)2}}{\sigma_{v}^{(s)2}}\mathbf{I}\right)^{-1}\right), \quad (13)$$

463 where *M* is the number of variants. We replace σ_v^2 in the last term by its current estimate $\sigma_v^{(s)2}$ to 464 obtain a close-form expression. Note that in Equation (13), $\frac{\sigma_{\alpha}^{(s)2}}{\sigma_v^{(s)2}}$ is usually replaced by $\frac{1}{\sigma_v^{(s)2}}$ to

465 avoid non-identifiability issues²².

466 When the profile likelihood converges, TGVIS estimates σ_{α}^2 as follows:

467
$$\sigma_{\alpha}^{(s+1)2}$$

468
$$= \frac{1}{M} \left(\widehat{\mathbf{a}} - \mathbf{R} \left(\widehat{\mathbf{B}} \mathbf{\theta}^{(s+1)} + \mathbf{\gamma}^{(s+1)} + \mathbf{\upsilon}^{(s+1)} \right) \right)^{\mathsf{T}} \mathbf{R}^{-1} \left(\widehat{\mathbf{a}} - \mathbf{R} \left(\widehat{\mathbf{B}} \mathbf{\theta}^{(s+1)} + \mathbf{\gamma}^{(s+1)} + \mathbf{\upsilon}^{(s+1)} \right) \right).$$
(14)

469 Bayesian Information Criterion for Summary Data

470 Based on Equation (3), we define the BIC for summary data:

471
$$BIC = \log(\sigma_{\alpha}^2) + \frac{\log M}{M} df, \quad (15)$$

where *M* is the number of IVs and df is the degree of freedom of the model⁵². In practice,
$$\sigma_{\alpha}^2$$
 is
replaced by its empirical estimate $\hat{\sigma}_{\alpha}^2$, and df is the sum of non-zero causal effect estimates and
non-zero direct causal variant estimates. Our default setting assumes *L* can be 2,3,4,5,6,7, or 8
and uses BIC to select the optimal *L* among them. We found that when considering the

It is made available under a CC-BY-ND 4.0 International license .

- 476 infinitesimal effect, it tends to capture variants with very small effects that SuSiE does not
- 477 identify, making it rare for *L* to exceed 8 in practice.

478 **Pratt index**

479 We use the Pratt index to assess the contribution of a gene-tissue pair. For a general linear

480 model:
$$y_i = \sum_{j=1}^p X_j \beta_j + \epsilon_i$$
, the Pratt index of x_{ij} is defined as $V_j = \beta_j \times b_j$, where $b_j =$

- 481 $\operatorname{cov}(y, X_j)$. This definition assumes standardization where $\operatorname{E}(y) = \operatorname{E}(X_j) = 0$ and $\operatorname{var}(y) =$
- 482 $\operatorname{var}(X_j) = 1, 1 \le j \le p$. The Pratt index measures the contribution of a variable in a linear
- 483 model because $R^2 = \sum_{j=1}^p V_j$ where $R^2 = \operatorname{var}(\sum_{j=1}^p X_j \beta_j)/\operatorname{var}(y)$. In practice, the Pratt index
- 484 can be estimated by $\hat{V}_j = \hat{\beta}_j \times \hat{b}_j$, where \hat{b}_j is the sample correlation between X_j and y.
- 485 The proportion of variance explained (PVE) is defined as $PVE_j = \beta_j^2$, assuming that all variables
- 486 are standardized. The Pratt index has two key advantages over PVE: (1) Pratt indices are additive
- 487 across variables, and (2) the sum of Pratt indices is the total trait variance explained by
- 488 covariates. In contrast, PVE lacks these advantages.

489 Pratt Index in TGVIS

490 Wee show how to yield the Pratt index V_{jt} in practice. We first estimate the marginal correlation:

491
$$\tilde{\delta}_{jt} = c \widehat{o} \widehat{r} (\widehat{\beta}_{jt}, \widehat{a}) = \frac{\widehat{\beta}_{jt}^{\mathsf{T}} \widehat{a}}{\sqrt{\widehat{\beta}_{jt}^{\mathsf{T}} \mathbf{R} \widehat{\beta}_{jt}} \sqrt{\widehat{a}^{\mathsf{T}} \mathbf{R}^{-1} \widehat{a}}}.$$
 (16)

492 As for the causal effect estimate $\hat{\theta}_{jt}$, we apply the transformation

493
$$\tilde{\theta}_{jt} = \hat{\theta}_{jt} \frac{\sqrt{\hat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}} \mathbf{R} \hat{\boldsymbol{\beta}}_{jt}}}{\sqrt{\hat{\mathbf{a}}^{\mathsf{T}} \mathbf{R}^{-1} \hat{\mathbf{a}}}}, \quad (17)$$

It is made available under a CC-BY-ND 4.0 International license .

494 since the Pratt index requires the covariates and trait are all standardized. Thus, the Pratt index of

495 the (j, t)th gene-tissue pair is

496
$$\hat{V}_{jt} = \tilde{\theta}_{jt} \times \tilde{\delta}_{jt} = \hat{\theta}_{jt} \frac{\hat{\boldsymbol{\beta}}_{jt}^{\mathsf{T}} \hat{\mathbf{a}}}{\hat{\mathbf{a}}^{\mathsf{T}} \mathbf{R}^{-1} \hat{\mathbf{a}}}.$$
 (18)

497 Since Pratt indices are additive, the Pratt index of a credible set is simply calculated as

498
$$\widehat{V}_{cs_l} = \sum_{j \in cs_l} \widehat{V}_j. \quad (19)$$

499 Note that the Pratt index is only comparable within the same locus, as it represents the ratio of

500 the variance explained by the variable to the total variance of the trait.

501 It is worth comparing the gene-tissue pair, direct causal variant, and infinitesimal effect

502 contributions at a locus. To simplify the estimation, we consider the linear predictors of all gene-

tissue pairs and pleiotropy:

504
$$\widetilde{\mathbf{\eta}}_{\theta} = \mathbf{R}^{\frac{1}{2}} \widehat{\mathbf{B}} \widehat{\mathbf{\theta}}, \quad \widetilde{\mathbf{\eta}}_{\gamma} = \mathbf{R}^{\frac{1}{2}} \widehat{\mathbf{\gamma}}, \quad \widetilde{\mathbf{\eta}}_{\upsilon} = \mathbf{R}^{\frac{1}{2}} \widehat{\mathbf{\upsilon}}.$$
 (20)

and $\tilde{\mathbf{a}} = \mathbf{R}^{-\frac{1}{2}} \hat{\mathbf{a}}$, where $\mathbf{R}^{-\frac{1}{2}}$ is specified to remove the correlations of $\hat{\mathbf{B}}$ and $\hat{\mathbf{a}}$. Then, the Pratt indices for the gene-tissue pairs, direct causal variants, and infinitesimal effects are

507
$$\hat{V}_{\theta} = \frac{\tilde{\eta}_{\theta}^{\top} \tilde{a}}{\|\tilde{a}\|_{2}^{2}}, \quad \hat{V}_{\gamma} = \frac{\tilde{\eta}_{\gamma}^{\top} \tilde{a}}{\|\tilde{a}\|_{2}^{2}}, \quad \hat{V}_{\upsilon} = \frac{\tilde{\eta}_{\upsilon}^{\top} \tilde{a}}{\|\tilde{a}\|_{2}^{2}}. \quad (21)$$

508 Threshold of Pratt index

509 We used the empirical data to determine the threshold for Pratt index to enhance the precision of

510 causal selection. Specifically, we employed K-means clustering with clusters to group the CS-

511 Pratt indices of all gene-tissue pairs and direct variants identified by TGVIS within the 95%

It is made available under a CC-BY-ND 4.0 International license .

512 credible sets. We hypothesize that one cluster contains credible sets with smaller CS-Pratt

- 513 values, which are more likely to include falsely causal variables. Interestingly, regardless of
- 514 whether we focus on gene-tissue pairs, direct causal variants, or both, the minimum value in the
- 515 cluster with the larger centroid consistently remains at 0.15 (Figure S34). Consequently, we set
- the threshold at CS-Pratt = 0.15 to prioritize the gene-tissue pairs and direct causal variants
- 517 identified by TGVIS, considering variables with CS-Pratt > 0.15 to have a higher likelihood of
- 518 being true causal.

519 Score test of variance of infinitesimal effects

520 In implementation, dynamically determining whether to consider the infinitesimal effect is a

521 clever empirical measure. Therefore, we apply the score test of the variance of the random effect

522 in the linear mixed model to test whether the variance of the infinitesimal effect is zero.

523 Specifically, we consider the following hypothesis testing problem:

524
$$H_0: \sigma_v^2 = 0, \quad v.s. \quad H_1: \sigma_v^2 > 0.$$
 (22)

The testing statistics of this hypothesis test is constructed according to Zhang and Lin⁵³. Let $\mathbf{A} = \begin{pmatrix} \mathbf{R} \hat{\mathbf{B}}_{\mathcal{M}_{\theta}}, \mathbf{R}_{\mathcal{M}_{\gamma}} \end{pmatrix}$ and $\boldsymbol{\vartheta} = \begin{pmatrix} \boldsymbol{\theta}_{\mathcal{M}_{\theta}}^{\mathsf{T}}, \boldsymbol{\gamma}_{\mathcal{M}_{\gamma}}^{\mathsf{T}} \end{pmatrix}^{\mathsf{T}}$. When $\sigma_v^2 = 0$ and $\sigma_v^2 > 0$, the covariance matrix of $\hat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta}$ are

528
$$\operatorname{cov}(\widehat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta}) = \sigma_{\alpha}^{2}\mathbf{R}, \quad \operatorname{cov}(\widehat{\boldsymbol{\alpha}} - \mathbf{A}\boldsymbol{\vartheta}) = \sigma_{\alpha}^{2}\mathbf{R} + \sigma_{v}^{2}\mathbf{R}^{2}, \quad (23)$$

respectively. Similar to estimating σ_v , we replace σ_{α}^2 by 1 to avoid non-identifiability. The score described in Zhang and Lin⁵³ defined the following three statistics:

531
$$u = \frac{1}{2} \| \hat{\alpha} - \mathbf{A}\vartheta \|_{2}^{2}, \quad e = \frac{1}{2} \operatorname{tr}(\mathbf{P}\mathbf{R}^{2}), \quad h = \frac{1}{2} \operatorname{tr}(\mathbf{P}\mathbf{R}^{2}\mathbf{P}\mathbf{R}^{2}), \quad (24)$$

It is made available under a CC-BY-ND 4.0 International license .

532 where
$$\mathbf{P} = \mathbf{R}^{-1} - \mathbf{R}^{-1}\mathbf{A}(\mathbf{A}^{\mathsf{T}}\mathbf{R}^{-1}\mathbf{A})^{-1}\mathbf{A}^{\mathsf{T}}\mathbf{R}^{-1}$$
. Under the null hypothesis, $u \sim \kappa \chi_{v}^{2}$ where $\kappa =$

533 h/(2e) and $v = 2e^2/h$. If the null hypothesis is accepted, we enforce $\mathbf{v}^{(s+1)} = 0$.

534 **Potential reasons leading to Infinitesimal effects**

Here we listed four possible reasons that can lead an infinitesimal effect. First, it has been
gradually understood that even within the same ethnic group, such as the European population,
different subgroups may have different genetic architectures, leading to different LD structures.

538 Therefore, it is natural to suspect that the LD structures of populations in the GTEx consortium

and those in traits GWAS differ, which results in

540
$$E(\hat{\boldsymbol{\alpha}}) = \mathbf{R}_{Meta}(\mathbf{B}\boldsymbol{\theta} + \boldsymbol{\gamma}), \quad E(\hat{\mathbf{b}}_{jt}) = \mathbf{R}_{GTEx}\boldsymbol{\beta}_{jt}.$$
 (25)

541 When we try to estimate β_{jt} using \mathbf{R}_{Meta} , then $\hat{\boldsymbol{\beta}}_{jt}$ is biased to β_{jt} , which generates infinitesimal 542 effect $\mathbf{v} = \sum_{jt} (\beta_{jt} - \hat{\boldsymbol{\beta}}_{jt}) \theta_{jt}$. It should be noted that the small sample size in the GTEx 543 consortium can also cause biased eQTL effect estimates, resulting in the appearance of 544 infinitesimal effects. There are other possible sources raising infinitesimal effects, such as (2) the 545 estimation errors of LD matrix, (3) the imputation errors of outcome GWAS effect sizes, and (4) 546 the absence of direct causal variants of outcome, which are shown in **Supplementary Materials**.

547 cTWAS and TGFM programs

For cTWAS, since its software is designed to be user-friendly to practical projects, it involves complex settings that are not ideal for simulations, such as requiring a reference panel in BED format and a .db file of eQTL fine-mapping data. Therefore, we directly utilize the principles of cTWAS to develop an R function that employs SuSiE for the first-stage selection of *cis*regulatory effects and the second-stage selection of causal and horizontally pleiotropic effects.

It is made available under a CC-BY-ND 4.0 International license .

553 At the time of writing this paper, the TGFM software has not yet been released. Therefore, we

did not consider the first step of cTWAS to estimate two universal prior parameters using the EM

algorithm across all loci in the genome. Instead, we restrict cTWAS simulations to a single locus.

556 In addition, we applied the following setting for cTWAS, TGFM and TGVIS: for the prior

557 weight π in SuSiE, we applied $\pi = p^{-1}$ for gene-tissue pairs and $\pi = M^{-1}$ for variants, where

558 *p* represents the number of gene-tissue pairs and *M* the number of variants.

559 To improve computational efficiency, we applied a slightly different resampling scheme

560 compared the original TGFM. Specifically, we first resampled the eQTL effects from the

561 posterior for 25 times, calculated their mean as $\hat{\beta}_{it}^{t_i}$ and used these means to estimate $\hat{\theta}^{t_i}$

and $\hat{\gamma}^{t_i}$. This procedure was repeated 100 times, recording the estimates and PIP for each

iteration. We then compute the mean of $t_1 \times t_2$ resampled eQTL effects, $\hat{\beta}_{it}^{TGFM}$, and estimate the

564 empirical $\hat{\theta}^{TGFM}$ and $\hat{\gamma}^{TGFM}$. The PIPs of $\hat{\theta}^{TGFM}$ and $\hat{\gamma}^{TGFM}$ were taken as the empirical PIPs

565 given by SuSiE in each resampling iteration. Finally, we recorded the credible sets of variables

from the final step and calculated the PIPs and Pratt indices of credible sets by summing the

567 individual PIPs and Pratt indices of variables within each credible set.

568 Simulation Settings

569 We simulated 20 genes across 5 tissues, resulting in p = 100 gene-tissue pairs. Correlations were

570 simulated both within and between genes across tissue. The first and last gene-tissue pairs were

571 designated as causal, with effect sizes of $\theta_1 = 1$ and $\theta_{100} = -1$, respectively. The total number

572 of variants was M = 400, with only 1,2,3 or 4 of them being eQTLs with non-zero effects for

573 each gene-tissue pair, while the remaining variants were associated with the trait due to LD. We

574 set 4 different sample sizes for the eQTL data ($n_{eQTL} = 100, 200, 400, 800$) and a fixed trait

It is made available under a CC-BY-ND 4.0 International license .

575 GWAS sample size $n_{trait} = 0.5$ M. Infinitesimal effect were generated from a normal 576 distribution, and gene-tissue pairs, direct causal variants, and infinitesimal effects together were 577 set to explain the trait heritability. For example, when only gene-tissue pairs and infinitesimal 578 effects are present, they each explain 50% of the local heritability for the outcome. When all 579 three are present, each explains 33% of the local heritability for the outcome. The detailed 580 settings, along with corresponding R codes, are provided in Section 2 of the **Supplementary** 581 **Materials**.

582 GWAS summary data

We conducted a meta-analysis on a subset of the 45 metabolic and cardiovascular traits. The 583 584 publicly available data for these traits are listed in **Table S1**, while the MVP GWAS summary 585 statistics can be accessed through dbGAP under accession number phs001672.v7.p1. For the 586 pleiotropy traits of SBP and DBP, we applied the approach developed in Zhu et al.³² using the 587 most recent GWAS summary statistics of SBP and DBP. To perform the meta-analysis, we used 588 METAL⁵⁴. We performed the meta-analysis on the Z-scores, weighting by the sample sizes of 589 the meta-analysis datasets. For binary trait, we always use the effective sample size n_{eff} . We 590 used CHR:BP (in GRCH37) as the identifier.

591 EQTL summary data

- 592 We utilized bulk eQTL and sQTL summary statistics from 28 tissues provided by GTEx¹² (with
- sample size N ranging from 34.4 (Lymphocytes) to 179.5 (Muscle Skeletal)), as well as
- additional eQTL summary statistics from tubulointerstitial³³ (N=311), kidney glomerular³³
- 595 (N=240), and islet³⁴ (N=420) tissues (**Table S2**).

596 Linkage Disequilibrium Reference Panel

It is made available under a CC-BY-ND 4.0 International license .

597 Our study used variants from the UKBB project conducted by Neale's lab, which initially

includes 13 million SNPs. We selected approximately 9.3 million SNPs with a minor allele

frequency greater than 0.01 for our analysis. We also identified the top 9,620 unrelated

600 individuals from approximately 500,000 individuals in the UKBB (Field ID: 22828), consisting

of 5,205 females and 4,475 males. Data from these 9.3 million SNPs were extracted for these

602 individuals to construct our LD reference panel.

603 Clumping and Thresholding

604 We restricted the studied regions to those within 1MB of the genome-wide significant loci for

605 these traits. These loci were identified using the clumping and thresholding (C+T) method in

606 PLINK⁵⁵: --clump-kb 1000, --clump-p1 5E-8, --clump-p2 5E-8, and --clump-r2 0.01.

607 We recommend using C+T to filter out variants in high LD, which prevents the inclusion of

numerous highly correlated or redundant variants in the analysis, which can unnecessarily

609 complicate the model and result in multiple credible sets consisting of these variants. We

610 evaluated the minimum P-value of each variant across gene-tissue pairs in eQTL/sQTL data. In

611 PLINK, we applied the C+T with the following parameters: --clump-kb 1000, --clump-p1 1E-5, -

612 -clump-p2 1E-5, and --clump-r2 0.5. Given that the true causal variant for a trait might not be

613 included in the eQTL/sQTL variants, we combined these variants from outcome GWAS

614 satisfying P < 5E-8 and r^2 <0.5.

615 **Removing gene-tissue pairs based on significance in S-Predixcan**

616 We used the minimum P-value from S-Predixcan and a modifier accounting for direct causal

617 variants (**Supplementary Materials**) to exclude eGenes/sGene with P > 0.05. These weak filters

618 will eliminate redundant gene-tissue pairs, thereby reducing the model's dimensionality. Since

It is made available under a CC-BY-ND 4.0 International license .

- our goal is fine-mapping the causal gene-tissue pairs and identifying direct causal variants on the
- 620 GWAS loci with significant signals, it will not induce a winner's curse.

621 Searching causal gene-tissue pairs missed by univariable TWAS

We compared the causal gene-tissue pairs identified by TGVIS and TGFM with the significant gene-tissue pairs identified by S-PrediXcan. We considered genes with P < 0.05/20,000 as significant gene-tissue pairs in tissue specific S-PrediXcan analysis. We did not adjust for number of tissues. We then searched the gene-tissue pairs identified by TGVIS or TGFM but

626 missed by S-PrediXcan.

627 Obtaining annotation scores from FAVOR and performing differential annotation tests

628 We combined the direct causal variants and xQTLs of causal gene-tissue pairs identified by

629 TGVIS or TGFM across all 45 traits into two separate files and uploaded them to the FAVOR

online platform³⁵ to obtain annotation scores for these variants. We performed Wilcoxon signed-

rank test with both "less" and "greater" as alternative hypotheses for determining the direction of

632 shift location and calculated corresponding P-values. We used the R package FDREstimation to

633 convert the P-values to FDR Q-values using the Benjamini–Yekutieli (BY) procedure.

Annotations with Q-values less than 0.05 were considered to have significantly different scores.

635 Mapping major trait relevant tissues

For TGVIS, a 95% credible set often includes multiple gene-tissue pairs. In such cases, we calculated the proportion of each tissue appearing among these pairs, allowing the number of tissues in a causal credible set of gene-tissue pairs to be fractional. For TGFM, we first removed the gene-tissue pairs with PIPs < 0.5, and then applied the same procedure to map the dominant tissues.

It is made available under a CC-BY-ND 4.0 International license .

641 Enrichment of identified causal genes in lipids silver gene list and druggable gene database

- 642 We applied the following strategy to map silver genes. First, we checked each credible set to see
- 643 if any genes are part of the silver gene list; if so, we counted 1. If no silver gene was present, we
- then checked if any genes in the credible set were among the nearby genes; if so, we also
- 645 counted 1. In other words, each credible set of gene-tissue pairs was counted only once. For
- TGFM, we first removed the gene-tissue pairs with PIPs < 0.5, and then applied the same
- 647 procedure as TGVIS to count the silver and nearby genes. Similar to the mapping procedure for
- 648 silver genes, we examined each credible set identified as causal to see if it contained any
- 649 druggable genes. If a druggable gene is present, we count it once.
- 650 We used the following statistics to compare the enrichments of TGVIS and TGFM. For example,
- regarding TGVIS and a given trait, we consider three metrics: the number of causal genes
- identified by TGVIS, the overlap between genes identified by TGVIS and those in the drug-
- target list, and the ratio of these two metrics (referred to as Ratio hereafter). To compare whether
- TGVIS or TGFM had a higher enrichment across traits, we performed a paired t-test using two

655 vectors of Ratio.

656 Colocalization of credible sets

657 We use colocalization to evaluate the causal credible sets identified by TGFM and TGVIS.

658 Within each region, we select variants from the outcome GWAS with P-values less than 5E-5

and $r^2 < 0.81$ for colocalization analysis. We perform fine-mapping on both the outcome and the

- 660 gene-tissue pairs within credible sets using SuSiE, then calculate the posterior probability for
- hypothesis H_4 , i.e., both traits are associated and share the same single causal variant, between
- each outcome and exposure pair using Coloc-SuSiE. We use a posterior probability of H_4 greater

It is made available under a CC-BY-ND 4.0 International license .

than 0.5 as the threshold to determine colocalization evidence between gene-tissue pairs and theoutcome; notably, as long as at least one variant meets this criterion, it suffices.

665 Mendelian Randomization using pQTL summary data

666 We performed both univariable and multivariable MR using pQTLs of protein abundance as IVs 667 to evaluating the identified causal tissue-gene pairs. Because to the lack of tissue-specific protein data, we focused on a subset of pGenes identified in blood tissues provided by Sun et al.¹⁰. We 668 669 selected independent, genome-wide significant pQTLs for each protein as IVs. The selection 670 method for independent IVs was C+T (--clump-kb 1000 --clump-p1 5e-8 --clump-p2 5e-8 --671 clump-r2 0.01 using PLINK), with LD reference panels consisting of the 9,680 individuals and 672 9.3M variants from UKBB. We applied five univariable MR methods: MRMedian⁵⁶, IMRP⁵⁷, MRCML⁵⁸, MRCUE⁵⁹, and MRBEE⁶⁰. Both MRCUE and MRBEE account for sample overlap, 673 674 with sample overlap correlations estimated using insignificant variants. We used the R package 675 FDREstimation to convert the P-values obtained by these methods to FDR Q-values, using "BY" 676 as the adjustment method. A pGene was considered significant if it was identified as such by at 677 least four methods. We also conducted an analysis comparing the enrichments of TGVIS and 678 TGFM, where the three corresponding metrics are: the overlap between causal genes identified by TGVIS or TGFM and the pGenes reported in Sun et al.¹⁰, the number of significant pGenes 679 680 identified in univariable MR analysis, and the ratio of these two metrics.

- 681 Author contributions
- 682 Y.Y and X.Z conceived and designed the study. Y.Y. performed all analysis. Y.Y and X.Z.
- 683 drafted the manuscript. N.L. edited the manuscript. X.Z. supervised this project.
- 684 Acknowledgments

It is made available under a CC-BY-ND 4.0 International license .

- This work was supported by grant HG011052 and HG011052-03S1 (to X.Z.) from the National
- 686 Human Genome Research Institute (NHGRI), USA.

687 **Declarations of interests**

688 The authors declare no competing interests.

689 **Ethics approval**

- 690 The study was approved by the institutional review board (IRB number: STUDY20180592) at
- 691 Case Western Reserve University

692 Data Availability

- 693 The GWAS summary data, eQTL summary data, and pQTL summary data used in this study can
- be downloaded from the "Data available" section of the literature listed in Table S1-S2. The
- 695 GTEx summary data can be obtained from https://gtexportal.org/home/downloads/adult-gtex/qtl.
- 696 The GWAS data in the million veteran program (MVP) are available through database of
- 697 genotypes and phenotypes (dbGAP) under accession number phs001672.v7.p1. The individual-
- level data from the UKBB used for estimating the LD matrix was accessed through ApplicationID: 81097.

700 Code Availability

- 701 The code for the analyses presented in this paper is available in the **Supplementary Materials**,
- 702 complete with step-by-step instructions. The TGVIS R package can be downloaded from
- 703 https://github.com/harryyiheyang/TGVIS.

It is made available under a CC-BY-ND 4.0 International license .

704 **References**

- 1. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of
- 706 lipids. *Nature* **600**, 675–679 (2021).
- 2. Yengo, L. et al. A saturated map of common genetic variants associated with human
- 708 height. *Nature* **610**, 704–712 (2022).
- 3. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.
- 710 *Nature* **627**, 347–357 (2024).
- 4. Mostafavi, H., Spence, J. P., Naqvi, S. & Pritchard, J. K. Systematic differences in discovery
- of genetic effects on gene expression and complex traits. *Nat. Genet.* **55**, 1866–1875
- 713 (2023).
- 5. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple
 causal variants. *PLOS Genet.* **17**, e1009440 (2021).
- 6. Gamazon, E. R. et al. A gene-based association method for mapping traits using
- 717 reference transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).
- 718 7. Gkatzionis, A., Burgess, S. & Newcombe, P. J. Statistical methods for cis-Mendelian
- randomization with two-sample summary-level data. *Genet. Epidemiol.* **47**, 3–25
- 720 (2023).
- 8. Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association
 studies. *Nat. Genet.* 51, 592–599 (2019).
- 723 9. Li, Y. I. *et al.* RNA splicing is a primary link between genetic variation and disease.
- *Science* **352**, 600–604 (2016).
- 10. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
- 726 Biobank. *Nature* **622**, 329–338 (2023).

- 727 11. Amariuta, T., Siewert-Rocks, K. & Price, A. L. Modeling tissue co-regulation estimates
- tissue-specific contributions to disease. *Nat. Genet.* **55**, 1503–1511 (2023).
- 12. The GTEx Consortium *et al.* The GTEx Consortium atlas of genetic regulatory effects
- 730 across human tissues. *Science* **369**, 1318–1330 (2020).
- 13. Zhao, S. *et al.* Adjusting for genetic confounders in transcriptome-wide association
- studies improves discovery of risk genes of complex traits. *Nat. Genet.* **56**, 336–347
- 733 (2024).
- 14. Strober, B. J., Zhang, M. J., Amariuta, T., Rossen, J. & Price, A. L. Fine-mapping causal
- tissues and genes at disease-associated loci. Preprint at
- 736 https://doi.org/10.1101/2023.11.01.23297909 (2023).
- 737 15. Burgess, S. & Thompson, S. G. *Mendelian Randomization*. (Chapman and Hall/CRC,
 738 2021). doi:10.1201/9780429324352.
- 16. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
- selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser. B
- 741 Stat. Methodol. 82, 1273–1300 (2020).
- 742 17. Cui, R. *et al.* Improving fine-mapping by modeling infinitesimal effects. *Nat. Genet.* 56,
 743 162–169 (2024).
- 744 18. Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with
- the "Sum of Single Effects" model. *PLOS Genet.* **18**, e1010299 (2022).
- 746 19. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from
- genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- 748 20. Liang, Y., Nyasimi, F. & Im, H. K. On the problem of inflation in transcriptome-wide
- 749 association studies. Preprint at https://doi.org/10.1101/2023.10.17.562831 (2023).

- 750 21. Sidorenko, J. *et al.* Genetic architecture reconciles linkage and association studies of
- 751 complex traits. *Nat. Genet.* (2024) doi:10.1038/s41588-024-01940-2.
- 752 22. Wood, S. N. Fast stable restricted maximum likelihood and marginal likelihood
- 753 estimation of semiparametric generalized linear models. J. R. Stat. Soc. Ser. B Stat.
- 754 *Methodol.* **73**, 3–36 (2011).
- 755 23. Aschard, H. A perspective on interaction effects in genetic association studies. *Genet.*756 *Epidemiol.* 40, 678–688 (2016).
- 757 24. Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
- 758 fibrillation biology. *Nat. Genet.* **50**, 1234–1239 (2018).
- 25. Surendran, P. *et al.* Discovery of rare variants associated with blood pressure regulation
- through meta-analysis of 1.3 million individuals. *Nat. Genet.* **52**, 1314–1332 (2020).
- 761 26. Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK
- 762 Biobank. Nat. Genet. 53, 185–194 (2021).
- 763 27. Pazoki, R. *et al.* Genetic analysis in European ancestry individuals identifies 517 loci
- associated with liver enzymes. *Nat. Commun.* **12**, 2579 (2021).
- 765 28. Young, W. J. *et al.* Genetic analyses of the electrocardiographic QT interval and its
- components identify additional loci and pathways. *Nat. Commun.* **13**, 5144 (2022).
- 767 29. Ghouse, J. *et al.* Genome-wide meta-analysis identifies 93 risk loci and enables risk
- 768 prediction equivalent to monogenic forms of venous thromboembolism. *Nat. Genet.* **55**,
- 769 399–409 (2023).
- 30. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes
- for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815
- 772 (2022).

- 31. Roychowdhury, T. et al. Genome-wide association meta-analysis identifies risk loci for
- abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. *Nat. Genet.*
- **55**, 1831–1842 (2023).
- 32. Zhu, X., Zhu, L., Wang, H., Cooper, R. S. & Chakravarti, A. Genome-wide pleiotropy
- analysis identifies novel blood pressure variants and improves its polygenic risk scores.
- 778 *Genet. Epidemiol.* **46**, 105–121 (2022).
- 33. Han, S. K. *et al.* Mapping genomic regulation of kidney disease and traits through highresolution and interpretable eOTLs. *Nat. Commun.* 14, 2229 (2023).
- 781 34. Viñuela, A. *et al.* Genetic variant effects on gene expression in human pancreatic islets
- and their implications for T2D. *Nat. Commun.* **11**, 4912 (2020).
- 783 35. Zhou, H. *et al.* FAVOR: functional annotation of variants online resource and annotator
- for variation across the human genome. *Nucleic Acids Res.* **51**, D1300–D1311 (2023).
- 785 36. Trajanoska, K. *et al.* From target discovery to clinical drug development with human
- 786 genetics. *Nature* **620**, 737–745 (2023).
- 787 37. GTEx Consortium *et al.* Estimating the causal tissues for complex traits and diseases.
- 788 Nat. Genet. 49, 1676–1683 (2017).
- 789 38. Arvanitis, M., Tayeb, K., Strober, B. J. & Battle, A. Redefining tissue specificity of genetic
- regulation of gene expression in the presence of allelic heterogeneity. *Am. J. Hum. Genet.*
- **109**, 223–239 (2022).
- 39. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple
- instrumental variables in Mendelian randomization: comparison of allele score and
- summarized data methods. *Stat. Med.* **35**, 1880–1906 (2016).

It is made available under a CC-BY-ND 4.0 International license .

- 40. Grant, A. J. & Burgess, S. An efficient and robust approach to Mendelian randomization
- with measured pleiotropic effects in a high-dimensional setting. *Biostatistics* **23**, 609–

797 625 (2022).

- 41. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
- expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825
- 800 (2018).
- 42. Kirk, T., Ahmed, A. & Rognoni, E. Fibroblast memory in development, homeostasis and
 disease. *Cells* 10, 2840 (2021).
- 43. Wittich, H. *et al.* Transcriptome-wide association study of the plasma proteome reveals
- cis and trans regulatory mechanisms underlying complex traits. *Am. J. Hum. Genet.* 111,
 445–455 (2024).
- 44. Ross, S. D. *et al.* Clinical outcomes in statin treatment trials: A meta-analysis. *Arch.*
- 807 Intern. Med. **159**, 1793 (1999).
- 45. Xu, Y. *et al.* Rs7206790 and rs11644943 in FTO gene are associated with risk of obesity
- in Chinese school-age population. *PLoS ONE* **9**, e108050 (2014).
- 810 46. Campos, A. I. *et al.* Boosting the power of genome-wide association studies within and
- 811 across ancestries by using polygenic scores. *Nat. Genet.* **55**, 1769–1776 (2023).
- 812 47. Yang, Y., Lee, D., Chakravarti, A. & Zhu, X. Partitioning tissue-specific heritability and
- 813 identifying tissue-specific causal genes of blood pressure traits using CRE annotations.

814 *Manuscript*.

- 815 48. Okamoto, J. *et al.* Probabilistic Fine-mapping of putative causal genes. Preprint at
- 816 https://doi.org/10.1101/2024.10.27.620482 (2024).

It is made available under a CC-BY-ND 4.0 International license .

- 49. Yazar, S. et al. Single-cell eQTL mapping identifies cell type–specific genetic control of
- autoimmune disease. *Science* **376**, eabf3041 (2022).
- 819 50. Claussnitzer, M. *et al. FTO* obesity variant circuitry and adipocyte browning in humans.
- 820 *N. Engl. J. Med.* **373**, 895–907 (2015).
- 51. Zhu, X. & Stephens, M. Bayesian large-scale multiple regression with summary statistics
- from genome-wide association studies. *Ann. Appl. Stat.* **11**, (2017).
- 823 52. Schwarz, G. Estimating the dimension of a model. *Ann. Stat.* **6**, (1978).
- 53. Zhang, D. & Lin, X. Hypothesis testing in semiparametric additive mixed models.
- 825 *Biostatistics* **4**, 57–74 (2003).
- 826 54. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

- 55. Purcell, S. *et al.* PLINK: A tool set for whole-genome association and population-based
 linkage analyses. *Am. J. Hum. Genet.* 81, 559–575 (2007).
- 830 56. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing
- 831 Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734–

832 1739 (2017).

- 833 57. Zhu, X., Li, X., Xu, R. & Wang, T. An iterative approach to detect pleiotropy and perform
- 834 Mendelian Randomization analysis using GWAS summary statistics. *Bioinformatics* **37**,
- 835 1390–1400 (2021).
- 58. Lin, Z., Xue, H. & Pan, W. Robust multivariable Mendelian randomization based on
- constrained maximum likelihood. *Am. J. Hum. Genet.* **110**, 592–605 (2023).

- 838 59. Cheng, Q., Zhang, X., Chen, L. S. & Liu, J. Mendelian randomization accounting for
- 839 complex correlated horizontal pleiotropy while elucidating shared genetic etiology. *Nat.*
- 840 *Commun.* **13**, 6490 (2022).
- 841 60. Lorincz-Comi, N., Yang, Y., Li, G. & Zhu, X. MRBEE: A bias-corrected multivariable
- 842 Mendelian Randomization method. *Hum. Genet. Genomics Adv.* 100290 (2024)
- 843 doi:10.1016/j.xhgg.2024.100290.

It is made available under a CC-BY-ND 4.0 International license .



Figure 1: Overview of TGVIS. A: A hypothetical causal diagram illustrating the relationships between variants (including xQTLs, direct causal variants, and non-causal variants), tissue-specific gene expressions, and an outcome in a *cis*-region, where the arrows indicate the flow of causal effects in the causal diagram. Variants may be in LD, with only a subset having cis-regulatory effects. Gene expressions or splicing events are tissue-specific and form a complex co-regulation network. Only molecular phenotypes directly connected to the outcome are considered causal. B: Locus-zoom plot of the LDL-C GWAS in the PCSK9 locus. The bottom panel displays the coding regions of genes located within this locus, including PCSK9, UPS24, BSND, etc. C: Workflow of TGVIS, consisting of three main steps. (I) Input, including GWAS summary data, eQTL summary data from multiple tissues, and LD matrix. (II) Preprocessing, including eQTL selection and prescreening. We applied S-Predixcan to pre-screen some noise pairs, aiming to reduce the dimension of the multivariable TWAS model to a reasonable scale. (III) Estimation, where TGVIS first selects the causal genetissue pairs and direct causal variants via SuSiE and then estimates the infinitesimal effect via REML. (IV) Output, including the causal effect estimate, direct causal effect estimate, and infinitesimal effect estimates. We output plots demonstrating the causal gene-tissue pairs, direct causal variants and predicted infinitesimal effects: (1) the Pratt indices and other statistics such as PIPs, estimates, SEs of causal gene-tissue pairs in the 95% credible sets, (2) the Pratt indices of the direct causal variants in the 95% credible sets, and (3) the best linear unbiased predictors of infinitesimal effects. The non-zero variance in output III in this figure suggests the non-zero contribution of infinitesimal effects.

It is made available under a CC-BY-ND 4.0 International license .



Figure 2: Simulation results comparing the performances of TGVIS, TGFM, cTWAS, Grant2022, and cisIVW with xQTL sample size = 200. A: The MSE of causal effect estimates under no pleiotropy, in the presence of direct causal variants, infinitesimal effects, and both. B: The true negative rate of identifying all 98 non-causal gene-tissue pairs under different scenarios i.e., no pleiotropy, in the presence of direct causal variants, infinitesimal effects, and both. This is equivalent to that if a method incorrectly identifies any non-causal pairs as causal, it will not be counted as a true negative event. C: Bar plots display the true positive rates of identifying all 2 causal gene-tissue pairs under different scenarios. D: The averaged number of identified direct causal variants by the different methods. The number of true causal variants were set to 0, 2, 0, and 2 for no-pleiotropy, direct-causal-variant, infinitesimal-effects, and direct-causal-variant and infinitesimal-effects, respectively. E: The averaged correlation of the true and estimated direct causal effects across simulations.



A. Number/Proportion of causal gene-tissue pairs identified by TGVIS B. Number/Proportion of causal gene-tissue pairs identified by TGFM

Figure 3: Summary of the identification of causal gene-tissue pairs and direct causal variants. A-B: The number and proportion of causal and likely novel causal gene-tissue pairs identified by TGVIS and TGFM, respectively. Likely novel gene-tissue pairs are defined as those not present in the list of significant gene-tissue pairs identified by univariable S-PrediXcan (P < 0.05/20000). The proportion refers to the average number of causal and likely novel causal gene-tissue pairs per locus. C: The number and proportion of direct causal variants identified by TGVIS and TGFM. D: The distribution of the number of traits affected by causal gene-tissue pairs. E-F: The distributions of scores for FathmmXF and Encode H3K9me3Sum annotations. Raincloud plots illustrate four classes: direct causal variants and xQTLs of causal gene-tissue pairs identified by TGVIS and TGFM. Pairwise Wilcoxon signed-rank test P-values are displayed at the top, while medians of annotation scores are shown at the bottom.



Figure 4: Genetic architecture inferred from the identification of causal gene-tissue pairs and direct causal variants. A: The ratio of identified causal gene-tissue pairs per credible set by TVGIS. Different gene-tissue pairs may share the same set of xQTLs, and end in the same credible set. B: The ratio of the number of causal eQTLs over the number of sQTLs per causal gene-tissue pair, indicating the distribution of eQTLs and sQTLs contributing to the gene-tissue pairs. C: The distribution of eGene and sGene in credible sets identified by TGVIS and TGFM. When a credible set contains multiple gene-tissue pairs, we calculate the proportion of eGenes and sGenes. D: The distribution of Pratt Index estimates for different traits, with a comparison between TGVIS and TGFM. In the boxplot, each point represents the Pratt Index of various molecular phenotypes within a single locus.



Figure 5: Distribution of major tissues for cardiometabolic traits. A: Heatmaps display the major tissues associated with each trait, identified by TGVIS. B: Heatmaps display the major tissues associated with each trait, identified by TGFM. The major gene-tissue pairs are cataloged based on stringent criteria (CS-Pratt > 0.15 for TGVIS and PIP > 0.5 for TGFM) and the proportions of major tissues derived from significant gene-tissue pairs for each trait are quantified. Hierarchical clustering is applied to arrange the heatmaps, utilizing the Ward2 method and Euclidean distance. C: Major tissues of lipid traits identified by TGVIS and TGFM. This panel shows bar plots detailing the number of causal gene-tissue pairs for various lipid traits, including HDL-C, LDL-C, TC, triglycerides, APOA1, and APOB, as identified by both TGVIS (top) and TGFM (bottom).



A. Proportions of causal credible sets with colocalization evidence

B. Number/Proportion of causal genes in FDA-approved drug-target gene list



Figure 6: Evaluation of identified gene-tissue pairs. A: The colocalized proportions of causal credible sets (under two criteria) yielded by TGVIS and TGFM, respectively. B: The numbers and proportions of causal cis-genes in the list of FDA-approved drug-target genes provided by Trajanoska et al., identified by TGVIS (left) and TGFM (right), respectively. C: The number of significant pGenes in univariable MR analysis divided by significant eGenes/sGenes in eQTL/sQTL analysis.



Figure 7: Locuszoom plots comparing the results of TGVIS and TGFM. A-C: LDL-C (*PCSK9* locus). D-F: LDL-C (*HMGCR* locus). G-I: CAD (*PHACTR1* locus), K-L: BMI (*FTO* locus). For each locus, we included three plots: (1) the GWAS of the trait, (2) the PIP of gene-tissue pairs and direct causal variants identified by the TGVIS and TGFM, and (3) the Pratt index of corresponding gene-tissue pairs and variants. For TGVIS, causality is determined by (1) the variables are in a 95% credible set and (2) the Pratt index of this credible set is larger 0.15. For TGFM, the causality is determined by (1) the individual PIP is larger than 0.5.